Clinical trials: SARS-COV-2 Infections
Immunogenicity, Efficacy
New Generation mRNA Booster Vaccine Against Emerging VOCs
Primary：Objectives ：SafetyTo describe the safetyprofile of all participants in each group up to 6months post-dose.Immunogenicity：To demonstrate the superiorityof neutralizing antibodyresponse in terms of geometric mean titers…
- Conditions
- Immunogenicity, Efficacy, Safety
- Trial name
- NCT05580159
- Testing
- SW-BIC-213, SARS-Cov-2 Vaccina(Vero Cell ) Inactivated
- Where
- Laos
- Volunteers
- 2,000 people, healthy volunteers welcome
- Sponsor
- Stemirna Therapeutics
SARS-CoV-2 Infection
To Evaluate the Safety, Tolerability and Pharmacokinetics of CT-P59 in Healthy Subjects
This is a Phase I study that randomized, double-blind, Placebo-controlled, Parallel Group, Single Ascending Dose Study to evaluate Safety, Tolerability and Pharmacokinetics of CT-P59 in Healthy Subjects.
- Trial name
- NCT04525079
- Testing
- CT-P59
- Where
- South Korea
- Volunteers
- 32 people
- Sponsor
- Celltrion
Perinatal Anxiety, Covid19
Augmented CBGT for Perinatal Anxiety During a Global Pandemic (COVID-19)
This study will evaluate the effectiveness of an augmented version of our current evidence-based Cognitive Behavioural Group Therapy (CBGT) for perinatal anxiety protocol with cognitive and behavioural strategies composed of…
- Trial name
- NCT04495803
- Testing
- Cognitive Behavioural Group Therapy for Perinatal Anxiety
- Where
- Canada
- Volunteers
- 68 people
- Sponsor
- St. Joseph's Healthcare Hamilton
COVID, Drug Effect
New Antiviral Drugs for Treatment of COVID-19
Background: In December 2019, SARS-CoV-2 was isolated on Vero E6 and Huh7 cell lines after an outbreak of pneumonia of unknown origin in Wuhan, Hubei Province, China.
- Trial name
- NCT04392427
- Testing
- Treatment group: will receive a combination of Nitazoxanide, Ribavirin and Ivermectin for a duration of seven days :
- Where
- Egypt
- Volunteers
- 100 people
- Sponsor
- Mansoura University
COVID-19, 2019 Novel Coronavirus Infection
Evaluating Clinical Parameters of COVID-19 in Pregnancy
Coronavirus infection, also known as COVID-19, has become a global pandemic with over 3 million cases and 250,000 deaths worldwide.
- Conditions
- COVID-19, 2019 Novel Coronavirus Infection, COVID-19 Infection
- Trial name
- COpregVID (NCT04470583)
- Where
- 2 sites in United Kingdom
- Volunteers
- 116 people, healthy volunteers welcome
- Sponsor
- Chelsea and Westminster NHS Foundation Trust
Burnout, Insomnia
Improving the Mental Health and Well Being of Healthcare Providers Through the Transcendental Meditation Technique
The level of stress-related disorders experienced by Healthcare Providers (HCPs) has increased due to the recent COVID-19 Pandemic, impacting patient care and provider shortages.
- Conditions
- Burnout, Insomnia, Well Being
- Trial name
- NCT05239429
- Testing
- Transcendental Meditation Technique
- Where
- United States
- Volunteers
- 130 people, healthy volunteers welcome
- Sponsor
- The Center for Clinical and Cosmetic Research
Acute Lung Injury, ALI
A Study of RLS-0071 in Patients With Acute Lung Injury Due to COVID-19 Pneumonia in Early Respiratory Failure
The aim of this study will test the safety, tolerability, and efficacy of RLS-0071 for approximately 28 days in comparison to a placebo control in patients with acute lung injury due to COVID-19 pneumonia in early respiratory…
- Conditions
- Acute Lung Injury, ALI, COVID-19
- Trial name
- NCT04574869
- Testing
- RLS-0071 10 mg/kg, RLS-0071 40 mg/kg
- Where
- United States
- Sponsor
- ReAlta Life Sciences, Inc.
COVID-19, Post-acute COVID-19 Syndrome
Hemostatic Profile of Post COVID-19/Long COVID-19 Patients
The present study aims at assessing long-term hemostatic profile of patients recovered from COVID-19 acute infection that remain asymptomatic (POST-COVID) versus patients with residual symptoms (LONG-COVID) through the employment…
- Trial name
- LCV (NCT05721066)
- Testing
- ClotPro assessment, Laboratory analysis, Interview
- Where
- Italy
- Volunteers
- 102 people
- Sponsor
- IRCCS Policlinico S. Donato
COVID-19
Clinical Trial of Efficacy and Safety of Sinovac's Adsorbed COVID-19 (Inactivated) Vaccine in Healthcare Professionals
This is a phase III clinical trial to assess efficacy and safety of the Adsorbed COVID-19 (inactivated) vaccine manufactured by Sinovac in health care professionals
- Trial name
- PROFISCOV (NCT04456595)
- Testing
- Adsorbed COVID-19 (inactivated) Vaccine
- Where
- 16 sites in Brazil
- Volunteers
- 12,688 people, healthy volunteers welcome
- Sponsor
- Butantan Institute
COVID-19
A Phase 1b Trial to Evaluate the Safety and Immunogenicity of a SARS-CoV-2 mRNA Chimera Vaccine Against COVID-19
This is a phase 1b, randomized, double-blind, positive control trial in healthy adults, intended to evaluate the safety and immunogenicity profile of RQ3013 in healthy adults primed with a two-dose inactivated vaccine 6-9 months…
- Trial name
- NCT05396573
- Testing
- RQ3013, Comirnaty
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Walvax Biotechnology Co., Ltd.
Covid19
Antisense Therapy to Block the Kallikrein-kinin Pathway in COVID-19
Up to 1/3 of all patients infected with COVID-19 can develop complications that require hospitalization. Severe pneumonia associated with acute respiratory distress syndrome (ARDS) is the most threatening and feared complication…
- Trial name
- ASKCOV (NCT04549922)
- Testing
- ISIS 721744, Normal Saline
- Where
- 3 sites in Brazil
- Volunteers
- 111 people
- Sponsor
- Hospital do Coracao
COVID-19, SARS-CoV-2 Infection
A Study to Evaluate the Immunogenicity and Safety of a Recombinant Protein COVID-19 Vaccine SCTV01E-1 in Population Aged Above 18 Years
The study is a randomized, double-blind Phase II study. It will evaluate the immunogenicity and safety of SCTV01E-1. Approximately 400 participants aged 18 years and older will be enrolled in this study.
- Trial name
- NCT05522829
- Testing
- SCTV01E-1 on D0, SCTV01E-1 on D28, SCTV01E-1 on D150
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Sinocelltech Ltd.
Covid19
Expanded Access to T89 for Treatment Use in Intermediate-size Patients Population With COVID-19
This expanded access use program will provide a botanical drug of T89 for treatment use in an intermediate-size population infected with SARS-CoV-2 who have severe COVID-19, or who are judged by a healthcare provider to be at…
- Trial name
- NCT04646031
- Testing
- T89 capsule
- Where
- United States
- Sponsor
- Tasly Pharmaceuticals, Inc.
Non-Covid, COVID-19
Comparison Between Early and Late Tracheostomy in Non-Covid and Covid
Tracheostomy is commonly indicated for the patient who is requiring long period of mechanical ventilation. Patient who require mechanical ventilation for >10 days and longer mostly get tracheostomized.
- Trial name
- CELT (NCT05465837)
- Testing
- Tracheostomy
- Where
- Oman
- Volunteers
- 156 people
- Sponsor
- Sultan Qaboos University
COVID-19 Pneumonia, COVID-19
Predictive Factors for Failure of Non-invasive Support Ventilation in Patients With COVID-19: A Retrospective Study.
During the progression of COVID-19, some patients may require noninvasive ventilation (NIV) or high-flow nasal catheter (CNAF) oxygen therapy.
- Trial name
- NCT05579080
- Testing
- noninvasive ventilation
- Where
- 2 sites in Brazil
- Volunteers
- 1,319 people
- Sponsor
- Universidade Federal do Rio de Janeiro
Covid19, Cytokine Storm
Intramuscular Effect of Polymerized Type I Collagen on the Cytokine Storm in COVID-19 Patients
SARS-CoV-2 infection induces a hyperinflammatory syndrome, causing the acute respiratory distress syndrome, massive lung cell destruction and, as a plausible sequelae, pulmonary fibrosis in COVID-19 patients.
- Conditions
- Covid19, Cytokine Storm, Regulation of Inflammatory Response, Pulmonary Fibrosis
- Trial name
- NCT04517162
- Testing
- Collagen-Polyvinylpyrrolidone
- Where
- Mexico
- Volunteers
- 90 people
- Sponsor
- Janette Furuzawa Carballeda
Covid19
TOcilizumab and Covid-19 : Risk of Severe INfection
SARS-CoV2 is responsible for a pandemic that has been evolving for approximately 18 months. The virus' capacity for dissemination and its virulence are responsible for significant morbidity and mortality.
- Trial name
- TOCSIN (NCT05017441)
- Where
- France
- Volunteers
- 1,200 people
- Sponsor
- Fondation Hôpital Saint-Joseph
Influenza, COVID-19
Routine Application of Point-of-care PCR Test to Identify and Direct Therapy for Acute Respiratory Infection in the Emergency Department Trial
The RAPID-ARIED Trial is a pragmatic, single-centre, parallel group, open-label, randomised controlled trial to be conducted in the Accident and Emergency Department of Queen Mary Hospital in Hong Kong.
- Conditions
- Influenza, COVID-19, Acute Respiratory Infections (ARIs)
- Trial name
- RAPID-ARIED (NCT06780566)
- Testing
- Point-of-care PCR testing for respiratory viruses, Laboratory PCR testing for respiratory viruses
- Where
- Hong Kong
- Volunteers
- 1,050 people
- Sponsor
- The University of Hong Kong
Sequelae, Fibrosis
Cohort Follow-up of Survivors of Hospitalization for COVID-19 During the 2nd Wave of the Epidemic in France
From July to September 2020, in a first uncontrolled cohort study, 478 patients who were hospitalized at Bicêtre hospital for COVID-19 and who survived were evaluated at 4 months (publication accepted at JAMA).
- Conditions
- Sequelae, Fibrosis, Post-COVID Syndrome, Post-traumatic Stress Disorder
- Trial name
- COMEBAC 2 (NCT04934202)
- Testing
- Teleconsultation, Outpatient clinic
- Where
- France
- Volunteers
- 500 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
COVID-19
Study on Safety and Clinical Efficacy of AZVUDINE in Initial Stage COVID-19 Patients (SARS-CoV-2 Infected)
Phase III, single-center with co-participating units, randomized, double-blind, parallel, placebo-controlled clinical study
- Trial name
- NCT05033145
- Testing
- AZVUDINE
- Where
- 7 sites in Brazil
- Volunteers
- 312 people
- Sponsor
- HRH Pharmaceuticals Limited
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.